CIRIUM
24.1.2023 09:01:33 CET | Business Wire | Press release
The new Cirium Fleet Forecast reveals demand for approximately 44,500 new aircraft globally over the next two decades, worth US$2.9 trillion.
The forecast published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium, is an independent outlook of the global passenger and freighter market for the next 20 years.
It reaffirms an encouraging long-term projection for the aviation industry and its recovery from the Covid-19 pandemic, predicting that 20-year aircraft deliveries will be 1% lower globally than predicted a year ago.
This comes despite Russia’s invasion of Ukraine, travel restrictions in China, and rising energy costs all emerging as influential factors during 2022.
The aviation industry’s recovery from the Covid-19 crisis in early 2020, has progressed significantly if unevenly across regions. Global aviation activity is predicted to reach 2019 levels in October.
Rob Morris, Ascend by Cirium’s Global Head of Consultancy, said: “The new Cirium Fleet Forecast shows a positive long-term outlook for aviation. The industry is undergoing structural changes but remains on course to return to traditional growth paths by 2025.”
“The global passenger fleet will be required to increase by around 22,000 aircraft to service passenger traffic, which we predict to grow 3.6% annually to reach 47,700 aircraft by the end of 2041.
“These new aircraft will be required to meet demand for air travel, but also to replace less efficient, older-generation types.”
Asia will account for over 40% of new deliveries
Asia-Pacific remains the key growth region for new deliveries, driven by China. The country is forecast to have the highest annual passenger traffic growth rate at over 6% and account for 19% of deliveries in 2041, ahead of all other Asia-Pacific countries, with a combined share of 22%.
North American and European airlines are projected to account for 21% and 17% of deliveries respectively. Middle East airlines will take 7% of deliveries, accounting for 14% in value terms due to the rich mix of higher value twin-aisle deliveries.
In the forecast, Russian capacity and traffic are assumed to decline in the near term. Combined with the complete cessation of Ukrainian civil aviation activity, Russia/CIS traffic is then forecast to stabilize at 70% of 2019 levels in 2024.
Demand for single-aisles will drive fleet growth
At the end of November 2022, the single-aisle fleet was within 2% of 2019 levels, but twin-aisle aircraft numbers were still down by 20%. The single-aisle fleet will grow faster by 3.7% annually, against 3.2% for twin-aisles as the recovery of long-haul traffic continues to lag. The regional aircraft fleet will rise more modestly, by 1.1% a year, with the turboprop fleet set to grow at a faster rate within the regional sector.
Forecast traffic growth over the long term will require the global passenger fleet to increase by around 22,000 aircraft, which equates to a 3.1% annual growth rate, taking the inventory to some 47,700 aircraft at the end of 2041.
The in-service passenger fleet is not forecast to return to 2019 levels until mid-2023, thus effectively losing up to four years of ‘normal’ fleet growth.
Airbus and Boeing will remain the two largest commercial aircraft OEMs, delivering an estimated 80% of aircraft between them and 88% by value through 2041. However, there is US$360 billion of demand for other OEMs or new programs.
The pressures to replace older, less-efficient types will increase
Close to 88% of the current passenger fleet is forecast to be retired from passenger service during the next 20 years. Freighters have longer useful economic lives, so approximately 70% of the current fleet will be retired by 2041.
Overall, there will be some 19,000 retirements from the end-2021 passenger fleet, plus a further 2,500 aircraft that leave the passenger fleet via cargo conversion.
As pressure to switch to more environmentally friendly aircraft grows, replacing less efficient older-generation types will be an increasingly important element of fleet planning. The Covid-19 crisis has seen relatively young aircraft being phased out, while those of older vintages may remain in storage until eventual scrapping.
The freighter boom continues, but may not persist
Freight capacity (available tonne kilometres or ATKs) is forecast to grow annually at 3.0% and traffic (FTKs) at 3.7%, relative to 2019. The forecast predicts the supply of some 3,560 freighter aircraft over the next 20 years, including 1,060 new builds (30%) worth US$130 billion, and 2,480 conversions of passenger aircraft (70%).
This is a similar volume and profile to that predicted in the previous forecast, reflecting the continued near-term boom in conversions triggered by the air-cargo market dynamics of the Covid-19 pandemic, including a short-term drop in passenger belly capacity, e-commerce growth and rising feedstock availability. Although the current conversion boom may not persist, it is enabling the replacement of older, less efficient aircraft.
To download an executive summary of the Cirium Fleet Forecast, [click here]
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005195/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
